Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response. Methods: This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years, mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8±1.3 log10 IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 × upper limit of normal. Results: After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8±19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076–4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of ≤2 log10 IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and ≤3 log10 IU/mL (n=11) and >3 log10 IU/mL (n=28), respectively. Conclusions: The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log10 IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration. (Clin Mol Hepatol 2016;22:382-389)
Abstract
Background/Aims: Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response. Methods: This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years, mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8±1.3 log10 IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 × upper limit of normal. Results: After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8±19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076–4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of ≤2 log10 IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and ≤3 log10 IU/mL (n=11) and >3 log10 IU/mL (n=28), respectively. Conclusions: The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log10 IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration. (Clin Mol Hepatol 2016;22:382-389)
참고문헌 (37)
- Chan HL, "Hepatocellular carcinoma and hepatitis B virus", Semin Liver Dis, 26, pp.153~161 (2006)
- European Association For The Study Of The Liver, "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
- Liaw YF, "Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study", Hepatology, 54, pp.91~100 (2011)
- 김영집, "Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients", Clinical and Molecular Hepatology, 19(3), pp.300~304 (2013), 대한간학회[DOI]
- Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
- Seto WK, "Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy", Hepatology, 58, pp.923~931 (2013)
- Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
- Song BC, "Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea", Hepatology, 32, pp.803~806 (2000)
- Lee CM, "Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation", J Hepatol, 37, pp.669~674 (2002)
- Ahn SH, "Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions", Hepatol Int, 4, pp.386~395 (2010)
- Van Nunen AB, "Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase", Gut, 52, pp.420~424 (2003)
- Liu F, "Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients", J Gastroenterol Hepatol, 26, pp.456~460 (2011)
- Ha M, "A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir", Arch Virol, 157, pp.285~290 (2012)
- Patwardhan VR, "Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides", nucleotides, 2014, pp.40, 804~810
- Jeng WJ, "Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients", Hepatology, 58, pp.1888~1896 (2013)
- Lee HW, "Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B", Hepatology, 51, pp.415~421 (2010)
- Pan X, "Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients", PLoS One, 8, pp.e68568~ (2013)
- Yeh CT, "Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression", J Clin Virol, 45, pp.114~118 (2009)
- Fung J, "The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion", Am J Gastroenterol, 104, pp.1940~1946 (2009)
- Reijnders JG, "Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B", Gastroenterology, 139, pp.491~498 (2010)
- Werle-Lapostolle B, "Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy", Gastroenterology, 126, pp.1750~1758 (2004)
- Chan HL, "Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response", Clin Gastroenterol Hepatol, 5, pp.1462~1468 (2007)
- Chan HL, "A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B", Hepatology, 52, pp.1232~1241 (2010)
- Brunetto MR, "Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers", Gastroenterology, 139, pp.483~490 (2010)
- Cai W, "On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients", J Clin Virol, 48, pp.22~26 (2010)
- Liang Y, "Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy", Aliment Pharmacol Ther, 34, pp.344~352 (2011)
- Chan HL, "Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients", Antivir Ther, 16, pp.1249~1257 (2011)
- Chen CH, "The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment", J Hepatol, 61, pp.515~522 (2014)
- Chen CH, "Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection", Clin Gastroenterol Hepatol, 13, pp.1984~1992 (2015)
- Chi H, "Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B", Aliment Pharmacol Ther, 41, pp.867~876 (2015)
- Seto WK, "Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study", Gut, 64, pp.667~672 (2015)
- Chu CM, "Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline", J Hepatol, 43, pp.411~417 (2005)